Nmda antagonists
CA 2025326 C · Owner: Marion Merrell Dow Canada Inc. · Inventors: Whitten, Jeffrey P.; Baron, Bruce M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a new class of beta-ketone, beta oxime and beta hydrazine phosphonate NMDA antagonists of the formula (I) or (Ia): (see formula I and II), wherein A, B, M R1 and R2 are variously defined, said, antagonists being useful in the treatment of a number of disease states, for example epilepsy, nerve trauma such as that caused by stroke, cardiac arrest, hypoglycemia and, physical damage to either the brain or spinal cord neurodegenerative diseases, anxiety and for the relief of pain.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 13, 1990 and granted April 24, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 13, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 13, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.